SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to expose patients with OA to calcitonin and to determine plasma
calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin. Also the purpose
is to assess the effect of different doses of oral calcitonin (0.6 mg and 0.8 mg oral)
compared to placebo on serum CTX-I and CTX-II. Finally to assess the tolerance profile of
different doses/formulations of oral calcitonin compared to placebo.